3,449 reports of this reaction
4.6% of all OLMESARTAN MEDOXOMIL reports
#1 most reported adverse reaction
SPRUE LIKE ENTEROPATHY is the #1 most commonly reported adverse reaction for OLMESARTAN MEDOXOMIL, manufactured by Cosette Pharmaceuticals, Inc.. There are 3,449 FDA adverse event reports linking OLMESARTAN MEDOXOMIL to SPRUE LIKE ENTEROPATHY. This represents approximately 4.6% of all 74,967 adverse event reports for this drug.
OLMESARTAN MEDOXOMIL has an overall safety score of 85 out of 100. Patients taking OLMESARTAN MEDOXOMIL who experience sprue like enteropathy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SPRUE LIKE ENTEROPATHY is moderately reported among OLMESARTAN MEDOXOMIL users, representing a notable but not dominant share of adverse events.
In addition to sprue like enteropathy, the following adverse reactions have been reported for OLMESARTAN MEDOXOMIL:
SPRUE LIKE ENTEROPATHY has been reported as an adverse event in 3,449 FDA reports for OLMESARTAN MEDOXOMIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
SPRUE LIKE ENTEROPATHY accounts for approximately 4.6% of all adverse event reports for OLMESARTAN MEDOXOMIL, making it one of the most commonly reported side effect.
If you experience sprue like enteropathy while taking OLMESARTAN MEDOXOMIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.